Lantern Pharma Doses First Patient in Japan for LP-300 Trial
The artificial intelligence (AI) company, Lantern Pharma, has announced that the first patient has been dosed in Japan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC). Dosing the first patient in Japan marks a key expansion of the HARMONIC™ trial into Asia, where never-smoker NSCLC patients are more prevalent than in Western populations. The trial is underway at five sites across Japan, including the National Cancer Center Japan, led by Dr. Yasushi Goto, a renowned lung cancer physician-researcher.
Lantern Pharma Doses First Patient in Japan for LP-300 Trial